Clinical trial
A Phase 1b Study of LY573636-sodium in Combination With Sunitinib Malate in Patients With Metastatic Renal Cell Cancer
NCT01258348 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Study of LY573636-sodium in Combination With Sunitinib Malate in Patients With Metastatic Renal Cell Cancer
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2008
- Completion date
- February 29, 2012
- Enrollment
- 21 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic renal cell cancer